Evaluation of growth inhibitory response of Resveratrol and Salinomycin combinations against triple negative breast cancer cells

This publication has 40 references indexed in Scilit:

• Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin
  Breast Cancer Research and Treatment, 2015
• Molecular characterization and targeted therapeutic approaches in breast cancer
  Breast Cancer Research, 2015
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
  International Journal of Cancer, 2014
• Salinomycin increases chemosensitivity to the effects of doxorubicin in soft tissue sarcomas
  BMC Cancer, 2013
• Salinomycin: A Novel Anti-Cancer Agent with Known Anti-Coccidial Activities
  Current Medicinal Chemistry, 2013
• Inhibition of the autophagic flux by salinomycin in breast cancer stem-like/progenitor cells interferes with their maintenance
  Autophagy, 2013
• Salinomycin – A New Cancer Drug Candidate
  Chemical Biology & Drug Design, 2011
• Triple negative breast cancer - prognostic factors and survival
  Radiology and Oncology, 2011
• Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein
  British Journal of Pharmacology, 2010
• Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
  Cell, 2009